+86-27-65522453 sales@sun-shinechem.com

Mavoglurant

Catalog No.: 17030612
Cas No.: 543906-09-8
Purity : 98% 
17030612 - Mavoglurant | CAS 543906-09-8

Catalog number : 17030612

CAS number : 543906-09-8

Molecular Formula : C19H23NO3 

Molecular Weight : 313.397 

Iupac Chemical Name : methyl (3aR,4S,7aR)-4-hydroxy-4-(m-tolylethynyl)octahydro-1H-indole-1-carboxylate 

Smile : O[C@@]1([C@@H]2CCN([C@@H]2CCC1)C(=O)OC)C#CC=1C=C(C=CC1)C

InChiKey : ZFPZEYHRWGMJCV-ZHALLVOQSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsAFQ056; AFQ-056; AFQ 056; Mavoglurant 
Molecular FormulaC19H23NO3 
Molecular Weight313.397 
Appearanceoff-white solid 
Purity98% 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. 
SmileO[C@@]1([C@@H]2CCN([C@@H]2CCC1)C(=O)OC)C#CC=1C=C(C=CC1)C
InChiKeyZFPZEYHRWGMJCV-ZHALLVOQSA-N
InChiInChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
Coming soon.
Mavoglurant, aslo known as AFQ056, is an experimental drug candidate for the treatment of fragile X syndrome. Mavoglurant exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder. 

543906-09-8 - Request Bulk Quote

×
543906-09-8 - Request Bulk Quote
Change